Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Amphastar Pharmaceuticals, Inc.
The main objective of this study is to evaluate the efficacy, dose-ranging and initial safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 25 to 180 mcg per dose in comparison to the DPI Placebo Control and the Active (Reference) Control. The study results of this study together with that of A006-B study will be utilized to determine the optimum final dose range of A006 for further clinical studies. The study will be conducted in male and female adult patients who have mild-to-moderate persistent asthma but are otherwise generally healthy.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
